Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 25;49(2):158-169.
doi: 10.3785/j.issn.1008-9292.2020.03.01.

[Pharmaceutical care for severe and critically ill patients with COVID-19]

[Article in Chinese]
Saiping Jiang  1 , Lu Li  1 , Renping Ru  2 , Chunhong Zhang  3 , Yuefeng Rao  1 , Bin Lin  4 , Rongrong Wang  1 , Na Chen  1 , Xiaojuan Wang  1 , Hongliu Cai  1 , Jifang Sheng  1 , Jianying Zhou  1 , Xiaoyang Lu  1 , Yunqing Qiu  1
Affiliations
Review

[Pharmaceutical care for severe and critically ill patients with COVID-19]

[Article in Chinese]
Saiping Jiang et al. Zhejiang Da Xue Xue Bao Yi Xue Ban. .

Abstract
in English, Chinese

Severe and critically ill patients with coronavirus disease 2019 (COVID-19) were usually with underlying diseases, which led to the problems of complicated drug use, potential drug-drug interactions and medication errors in special patients. Based on Diagnosis and treatment of novel coronavirus pneumonia (trial version 6), and Management of COVID-19: the Zhejiang experience, we summarized the experience in the use of antiviral drugs, corticosteroids, vascular active drugs, antibacterial, probiotics, nutrition support schemes in severe and critically ill COVID-19 patients. It is also suggested to focus on medication management for evaluation of drug efficacy and duration of treatment, prevention and treatment of adverse drug reactions, identification of potential drug-drug interactions, individualized medication monitoring based on biosafety protection, and medication administration for special patients.

2019冠状病毒病（COVID-19）重型、危重型患者往往合并基础疾病，用药种类复杂，存在潜在的药物相互作用、特殊人群用药等问题。本文依据《新型冠状病毒肺炎诊疗方案（试行第六版）》，基于《2019冠状病毒病（COVID-19）诊疗浙江经验》，总结重型、危重型患者选择抗病毒药物、糖皮质激素、血管活性药物、抗菌药物、微生态制剂、营养支持方案等经验，建议针对药物疗效和疗程评估、药物不良反应防治、潜在药物相互作用识别、基于生物安全防护的个体化用药监测以及特殊人群给药等进行重点用药管理，以期为COVID-19患者临床药物选择和用药管理提供参考。

PubMed Disclaimer

Figures

None
图1
2019冠状病毒病患者治疗药物监测实施过程中的生物安全防护
See this image and copyright information in PMC

References

    1. 中华人民共和国国家卫生健康委员会办公厅, 国家中医药管理局办公室.新型冠状病毒感染的肺炎诊疗方案(试行第六版)[A/OL].国卫办医涵[2020] 145号.(2020-02-18)[2020-02-28].. http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aef...
    1. 徐 凯进, 蔡 洪流, 沈 毅弘, et al. 2019冠状病毒病(COVID-19)诊疗浙江经验. http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2020.02.02. 浙江大学学报(医学版) 2020;49(2):147–157. doi: 10.3785/j.issn.1008-9292.2020.02.02. [徐凯进, 蔡洪流, 沈毅弘, 等.2019冠状病毒病(COVID-19)诊疗浙江经验[J].浙江大学学报(医学版), 2020, 49(2):147-157. DOI:10.3785/j.issn.1008-9292.2020.02.02.] - DOI
    1. 武汉同济医院新型冠状病毒肺炎救治协作组.重症新型冠状病毒感染肺炎诊疗与管理共识[A/OL].(2020-02-11)[2020-02-25].. http://health.people.com.cn/n1/2020/0211/c14739-31581678.html
    1. 中华预防医学会微生态学分会 中国消化道微生态调节剂临床应用共识(2016版) 中国微生态学杂志. 2016;28(6):621–631. doi: 10.13381/j.cnki.cjm.201606001. [中华预防医学会微生态学分会.中国消化道微生态调节剂临床应用共识(2016版)[J].中国微生态学杂志, 2016, 28(6):621-631. DOI:10.13381/j.cnki.cjm.201606001.] - DOI
    1. 中华人民共和国国家卫生健康委员会办公厅, 国家中医药管理局办公室.新型冠状病毒肺炎重型、危重型病例诊疗方案(试行第二版)[A/OL].国卫办医函[2020] 127号.(2020-02-14)[2020-02-28].. http://www.gov.cn/zhengce/zhengceku/2020-04/01/content_5497892.htm

MeSH terms